Pathophysiology and types of dyslipidemia in PCOS

被引：214

作者：

Diamanti-Kandarakis, Evanthia

Papavassiliou, Athanasios G.

Kandarakis, Stylianos A. ^{[1
]}

Chrousos, George P.

机构：

[1] Univ Athens, Sch Med, Dept Med 1, Laiko Gen Hosp,Endocrine Sect, GR-11527 Athens, Greece

[2] Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece

[3] Univ Athens, Dept Pediat 1, Agia Sophia Childrens Hosp, GR-11527 Athens, Greece

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2007年 / 18卷 / 07期

关键词：

D O I：

10.1016/j.tem.2007.07.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects women of reproductive age. PCOS shares components with the metabolic syndrome and has broad health implications. Lipid abnormalities, including elevated low-density lipoprotein (LDL), triglyceride levels and decreased high-density lipoprotein (HDL), are often found in women with PCOS. It is clear that obesity, insulin resistance and hyperandrogenism coexist in PCOS, and have independent and interactive effects on dyslipidemia, although the mechanisms of these interactions remain elusive. Here, we review the types and pathophysiology of dyslipidemia associated with PCOS and its related conditions.

引用

页码：280 / 285

页数：6

共 63 条

[1] The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue [J].